neuromuscular diseases in infants07d0901f-86b6-4cd0...jul 31, 2019 · systemic genetic disorders....
Post on 26-Sep-2020
5 Views
Preview:
TRANSCRIPT
Neuromuscular Diseases in Infants
SMA and Duchenne Muscular DystrophyTim Lotze, M.D.
Associate Professor of Pediatric NeurologyDirector, MDA Care CenterTexas Children’s Hospital
Baylor College of Medicine
Evaluation of Neuromuscular Disease
•Clinical History• Neurological Exam• Electrodiagnostics
• Electromyography• Nerve Conduction Studies
• Genetic studies or tests• Metabolic screening labs• Chromosomal Microarray• Whole Exome Sequencing• Candidate gene analysis
• MRI spine, roots, plexus, or muscle group
• Ultrasound• Muscle and nerve biopsies
How muscles get the message to moveBrain cell >> Spinal cord motor nerve cell >> Muscle
Congenital Hypotonia
Central= Brain and Spinal CordSystemic Genetic DisordersPerinatal brain asphyxiaMetabolic Disorders
Peripheral= Motor UnitAnterior Horn CellPeripheral NerveNeuromuscular JunctionMuscle
Spinal Muscular Atrophy (SMA)
• SMA is a disease that robs people of physical strength by affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe.
• Affects about 1 in 6000 to 10,000 live births
• It is was the #1 genetic cause of death for infants
• SMA is an inherited disorder and about 1 in 50 people are healthy carriers.
SMA TYPE I SMA TYPE II SMA TYPE III
• Onset < 6 months• Never achieve sitting• Throat weakness
• Weak cry• Aspiration
• Pulmonary weakness• Belly breathing
• Life span < 2 years
• Onset 6 -18 month• Can sit• Variable throat and pulmonary
weakness• Scoliosis• 70% alive at 25 years of age
• Onset > 18 months• Can walk• Variable throat and pulmonary
weakness• Scoliosis• Normal lifespan
2 copies SMN2 3 copies SMN2 > 3 copies SMN2
All type present with proximal arm and leg weakness, sparing the face, and normal intelligence
Clinical Presentation
SMA1• Severe hypotonia• Generalized muscular weakness (proximal > distal)• Deep-tendon reflexes can be decreased or absent.• Weak intercostal muscles with bell-shape-like chest
• "Belly-breathing" • Bulbar weakness
• Difficulties in feeding >> g-tube• Tongue fasciculation and weak cry
• Constipation, gastroesophageal reflux, metabolic dysfunction, weight loss and sleeping problems
• High-level cognitive functions seem to be spared.• Established practice paremeter treatment guidelines
What is the cause of SMA?• 95% of patients inherit 2 copies of an abnormal SMN1 gene. • SMN2 is nearly identical to SMN1 but is only able to produce the
fully functional protein 10% of the time
https://www.youtube.com/watch?v=fi6A5VUTC6Y
Nusinersen (Spinraza)
• FDA approved for SMA Dec 23, 2016• Nusinersen helps the motor nerve to
read the SMN2 recipe so missing SMN1 doesn’t matter
Triage Visit
Spinraza Delivery Process
$750K for first year and then $325K each year after
What’s next? Special Delivery- SMN1 Gene Replacement Therapy (Zolgensma)
http://www.curesma.org/news/avexis-reports-trial-results.html
$2.125 M for single dose
Zolgensma Outcomes
SMN1 Gene Transfer
• 11 of 12 (92%) achieved head control, 9 of 12 (75%) could roll a minimum of 180 degrees, and 11 of 12 (92%) could sit with assistance.
• 9 of 12 (75%) could sit unassisted for five seconds, 7 of 12 (58%) could sit unassisted for 10 seconds and 5 of 12 (42%) could sit unassisted for 30 seconds or more.
• Two patients could walk independently
http://www.curesma.org/news/avexis-reports-trial-results.htmlhttps://clinicaltrials.gov/ct2/show/NCT02122952?term=Avxs&rank=1
Duchenne Muscular Dystrophy
Muscle Disorders
Molecular mechanisms of muscular dystrophies: old and new players. Davies, K.E. and Nowak, K. J. Nature Reviews Molecular Cell Biology. Volume 7. Pg. 762—773. October 2006.
Duchenne Muscular Dystrophy• X-linked (deletion most common)• Symptom onset < 5 years• Loss of ambulation by age 12 years• Lifespan 20s+• Practice Guideline: Prednisone • Complications
• Cardiac >>> yearly ECHO/Holter at diagnosis/6 years• Pulmonary >>> pulmonary medicine at 10 years• Scoliosis >>> orthopedics• Contractures >>> PM&R and therapy services
Duchenne Musclar Dystrophy Progression
Gower’s Sign
Annals of NeurologyVolume 74, Issue 5, pages 637-647, 10 SEP 2013 DOI: 10.1002/ana.23982http://onlinelibrary.wiley.com/doi/10.1002/ana.23982/full#ana23982-fig-0006
Eteplirsen for the treatment of Duchenne muscular dystrophy
Useful Resources
• www.mdausa.org• https://www.parentprojectmd.org/• http://www.curesma.org/
Thanks, and please send along questions!
top related